HCP access has fallen below half of what it was two decades ago, and every commercial leader in life sciences knows the number. But the data hides a more uncomfortable truth: the real problem is rarely getting the meeting. It is what your reps do once they are in it.
The number everyone quotes
HCP access has dropped to less than half what it was in 2008. The stat appears in every commercial conference keynote, every enablement budget conversation, and every field-team town hall. Leaders manage around it constantly, and field teams feel it daily.
But fixation on the access number obscures a finding that complicates the whole narrative. A meaningful share of specialty physicians say they want to see reps more, not less. If the problem were purely structural, busy physicians, locked doors, gatekeeper systems, that desire would not exist. The appetite for valuable engagement is there. So the question shifts from why is access down to why aren't more physicians asking for your reps back.
The gap nobody measures
Braintrust's work inside pharmaceutical, biotech, and medical device commercial organizations surfaces the same pattern repeatedly: a substantial gap between how reps rate their own conversations and how HCPs rate those same conversations. Reps consistently believe they delivered more value than physicians report receiving.
That gap is not a product-knowledge problem or a compliance problem. It is a communication problem, and it has a neuroscience explanation that most field training never addresses.
What the physician's brain does first
When a rep walks into a physician's office, the HCP's brain runs a rapid threat assessment before the rep says a word. The limbic system determines whether this interaction is safe, familiar, or threatening, and the prefrontal cortex, responsible for rational evaluation, does not fully engage until that assessment clears. If the first signals trigger a threat response, the conversation is effectively over before the clinical evidence is presented. The physician is physically present but cognitively unavailable.
Most reps have never been taught this. They have been trained on product features, objection handling, and compliance guardrails. The neural mechanics of how their buyer actually processes the interaction were left out of the curriculum entirely.
Why leading with more data backfires
Standard life sciences training optimizes for information delivery. Reps learn to present clinical data, navigate payer conversations, and respond to competitive objections. These matter. They are also the skills that activate the fewest neural resources in the buyer.
Physicians are trained scientists with highly developed threat-detection honed by years of rep interactions. When a rep leads with data, the physician is not just evaluating the data. They are simultaneously evaluating the rep's credibility, motivations, and whether the conversation is worth continuing. Strong data and a lost room can happen at the same time, because the human evaluation runs in parallel.
What builds credibility with a scientifically trained buyer is not more data. It is demonstrated understanding of their world: the formulary pressure they face, the specific patient population they worry about, the conversation they had with a peer at their last conference. When a rep shows they understand the physician's context before presenting a solution, the brain's threat architecture shifts. A potential interruption becomes a potentially useful conversation.
Access is partly a consequence of conversation quality
Here is the reframe most commercial strategies miss: declining access is, in part, a downstream consequence of conversation quality. When physicians learn through experience that most rep interactions do not deliver useful information or respect their time, they rationalize restricting access as a productivity decision. Not out of dislike. Because the return on the interaction is not there.
That means access and conversation quality are not independent variables. Physicians who experience high-value interactions with a specific rep find ways to make time for that rep. The access structure softens for individuals who have proven they are worth it. Treating access as the primary lever while leaving conversation quality untouched optimizes for the wrong variable.
The one lever entirely within your control
Access will keep being shaped by forces outside your control: health-system consolidation, HCP time compression, digital-first engagement preferences, and regulatory constraints on how reps can interact. You can influence those at the margins. You cannot control them.
How your field teams communicate is different. The neural principles that govern how a physician evaluates trust, absorbs evidence, and decides whether a rep is worth their time are stable and learnable. They do not require regulatory approval to apply, and they do not depend on access-rate trends. Every interaction your reps earn is a finite, increasingly valuable resource. The organizations that invest in the science of how those interactions land will compound that advantage. The ones that keep optimizing access while leaving conversation quality on autopilot will keep reporting strong activity metrics and disappointing commercial outcomes.
If the commercial gap your organization is experiencing is real, it is worth a conversation. Reach out to the Braintrust team at braintrustgrowth.com/contact-us to talk through what improving conversation quality looks like in your specific commercial environment.
